• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

下一代纳米材料：推动眼部抗炎药物治疗。

Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.

机构信息

School of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.

Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, Education Ministry Key Laboratory of Medical Electrophysiology, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.

出版信息

J Nanobiotechnology. 2023 Aug 19;21(1):282. doi: 10.1186/s12951-023-01974-4.

DOI:10.1186/s12951-023-01974-4
PMID:37598148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10440041/
Abstract

Ophthalmic inflammatory diseases, including conjunctivitis, keratitis, uveitis, scleritis, and related conditions, pose considerable challenges to effective management and treatment. This review article investigates the potential of advanced nanomaterials in revolutionizing ocular anti-inflammatory drug interventions. By conducting an exhaustive analysis of recent advancements and assessing the potential benefits and limitations, this review aims to identify promising avenues for future research and clinical applications. The review commences with a detailed exploration of various nanomaterial categories, such as liposomes, dendrimers, nanoparticles (NPs), and hydrogels, emphasizing their unique properties and capabilities for accurate drug delivery. Subsequently, we explore the etiology and pathophysiology of ophthalmic inflammatory disorders, highlighting the urgent necessity for innovative therapeutic strategies and examining recent preclinical and clinical investigations employing nanomaterial-based drug delivery systems. We discuss the advantages of these cutting-edge systems, such as biocompatibility, bioavailability, controlled release, and targeted delivery, alongside potential challenges, which encompass immunogenicity, toxicity, and regulatory hurdles. Furthermore, we emphasize the significance of interdisciplinary collaborations among material scientists, pharmacologists, and clinicians in expediting the translation of these breakthroughs from laboratory environments to clinical practice. In summary, this review accentuates the remarkable potential of advanced nanomaterials in redefining ocular anti-inflammatory drug therapy. We fervently support continued research and development in this rapidly evolving field to overcome existing barriers and improve patient outcomes for ophthalmic inflammatory disorders.

摘要

眼科炎症性疾病，包括结膜炎、角膜炎、葡萄膜炎、巩膜炎和相关疾病，对有效管理和治疗构成了重大挑战。本文研究了先进纳米材料在眼科抗炎药物干预方面的潜在应用。通过对最新进展进行详尽分析，并评估潜在的益处和局限性，本综述旨在为未来的研究和临床应用确定有前途的方向。本综述首先详细探讨了各种纳米材料类别，如脂质体、树枝状大分子、纳米颗粒 (NPs) 和水凝胶，强调了它们在精确药物输送方面的独特性质和能力。随后，我们探讨了眼科炎症性疾病的病因和病理生理学，强调了创新治疗策略的迫切需要，并研究了最近使用基于纳米材料的药物输送系统进行的临床前和临床研究。我们讨论了这些前沿系统的优势，如生物相容性、生物利用度、控制释放和靶向输送，以及潜在的挑战，包括免疫原性、毒性和监管障碍。此外，我们强调了材料科学家、药理学家和临床医生之间开展跨学科合作的重要性，以加速这些突破从实验室环境向临床实践的转化。总之，本综述强调了先进纳米材料在重新定义眼科抗炎药物治疗方面的巨大潜力。我们强烈支持在这个快速发展的领域继续进行研究和开发，以克服现有障碍，改善眼科炎症性疾病患者的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/8f29b7aaf963/12951_2023_1974_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/bac68c6c228c/12951_2023_1974_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/b309eade3500/12951_2023_1974_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/418a8c7bfc0a/12951_2023_1974_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/7a6ef02a93e9/12951_2023_1974_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/ecf2c0dcd97c/12951_2023_1974_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/390f5f62a7c0/12951_2023_1974_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/c7e5f075a840/12951_2023_1974_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/a8c81ba313c4/12951_2023_1974_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/41091da22fbd/12951_2023_1974_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/4f830812d6cf/12951_2023_1974_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/c60bb088a7dc/12951_2023_1974_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/502abc3e5e7e/12951_2023_1974_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/9b564647c2dc/12951_2023_1974_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/8f29b7aaf963/12951_2023_1974_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/bac68c6c228c/12951_2023_1974_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/b309eade3500/12951_2023_1974_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/418a8c7bfc0a/12951_2023_1974_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/7a6ef02a93e9/12951_2023_1974_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/ecf2c0dcd97c/12951_2023_1974_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/390f5f62a7c0/12951_2023_1974_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/c7e5f075a840/12951_2023_1974_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/a8c81ba313c4/12951_2023_1974_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/41091da22fbd/12951_2023_1974_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/4f830812d6cf/12951_2023_1974_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/c60bb088a7dc/12951_2023_1974_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/502abc3e5e7e/12951_2023_1974_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/9b564647c2dc/12951_2023_1974_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e2/10440041/8f29b7aaf963/12951_2023_1974_Fig14_HTML.jpg

相似文献

1
Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.下一代纳米材料：推动眼部抗炎药物治疗。
J Nanobiotechnology. 2023 Aug 19;21(1):282. doi: 10.1186/s12951-023-01974-4.
2
Nanomaterials for ocular drug delivery.用于眼部药物输送的纳米材料。
Macromol Biosci. 2012 May;12(5):608-20. doi: 10.1002/mabi.201100419. Epub 2012 Apr 17.
3
Overview of Recent Advances in Nano-Based Ocular Drug Delivery.基于纳米的眼部药物输送的最新进展概述。
Int J Mol Sci. 2023 Oct 19;24(20):15352. doi: 10.3390/ijms242015352.
4
Nanomaterial-based ophthalmic drug delivery.基于纳米材料的眼科药物输送。
Adv Drug Deliv Rev. 2023 Sep;200:115004. doi: 10.1016/j.addr.2023.115004. Epub 2023 Jul 9.
5
Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.基于可生物降解聚合物的眼部疾病药物传递系统。
Int J Mol Sci. 2023 Aug 19;24(16):12976. doi: 10.3390/ijms241612976.
6
Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug.纳米技术介导的草药纳米系统在眼科药物中的应用。
Pharm Nanotechnol. 2024;12(3):229-250. doi: 10.2174/2211738511666230816090046.
7
Hydrogel-based ocular drug delivery systems for hydrophobic drugs.水凝胶基眼部药物传递系统用于疏水性药物。
Eur J Pharm Sci. 2020 Nov 1;154:105503. doi: 10.1016/j.ejps.2020.105503. Epub 2020 Aug 1.
8
Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics.促进纳米载体介导的眼部治疗药物递送的潜力释放。
Int J Pharm. 2024 Jun 10;658:124192. doi: 10.1016/j.ijpharm.2024.124192. Epub 2024 May 3.
9
Nanocarriers Based Ocular Therapeutics: Updates, Challenges and Future Prospectives.基于纳米载体的眼部治疗药物：最新进展、挑战与未来展望。
Curr Drug Res Rev. 2023;15(1):15-28. doi: 10.2174/2589977514666220913120718.
10
Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma.纳米系统在眼部药物输送中的进展：以小儿视网膜母细胞瘤为重点。
Molecules. 2024 May 11;29(10):2263. doi: 10.3390/molecules29102263.

引用本文的文献

1
Nanotherapies based on bacterial metabolism: Mechanisms, design and application.基于细菌代谢的纳米疗法：机制、设计与应用。
Mater Today Bio. 2025 Jul 18;34:102117. doi: 10.1016/j.mtbio.2025.102117. eCollection 2025 Oct.
2
Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.用于治疗眼部疾病的基于纳米医学的眼科药物递送系统
Int J Nanomedicine. 2025 Jul 21;20:9221-9249. doi: 10.2147/IJN.S532074. eCollection 2025.
3
Bovine ocular microbiome: the next frontier in managing Pinkeye in cattle.牛眼微生物群：牛红眼病防治的新前沿。

本文引用的文献

1
Aflibercept for the Treatment of Macular Edema Secondary to Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome.阿柏西普用于治疗特发性视网膜血管炎、动脉瘤和神经视网膜炎综合征继发的黄斑水肿。
Cureus. 2023 Apr 26;15(4):e38154. doi: 10.7759/cureus.38154. eCollection 2023 Apr.
2
Association of TBX21 gene polymorphisms and acute anterior uveitis risk in a Chinese population: A case-control study.中国人群中TBX21基因多态性与急性前葡萄膜炎风险的关联：一项病例对照研究。
Exp Eye Res. 2023 Apr;229:109417. doi: 10.1016/j.exer.2023.109417. Epub 2023 Feb 14.
3
Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: evaluation in equine eye.
Anim Microbiome. 2025 Jun 4;7(1):58. doi: 10.1186/s42523-025-00425-9.
4
Intraocular injectable hydrogels for the delivery of cells and nanoparticles.用于细胞和纳米颗粒递送的眼内注射水凝胶。
Mater Today Bio. 2025 Apr 12;32:101767. doi: 10.1016/j.mtbio.2025.101767. eCollection 2025 Jun.
5
Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases.用于自身免疫性疾病靶向给药的可生物降解及刺激响应性纳米材料
J Funct Biomater. 2025 Jan 14;16(1):24. doi: 10.3390/jfb16010024.
6
Advancements in nanohydroxyapatite: synthesis, biomedical applications and composite developments.纳米羟基磷灰石的进展：合成、生物医学应用及复合材料的发展
Regen Biomater. 2024 Nov 5;12:rbae129. doi: 10.1093/rb/rbae129. eCollection 2025.
7
Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy.纳米材料通过调控巨噬细胞自噬介导的结核病宿主导向治疗。
J Nanobiotechnology. 2024 Oct 8;22(1):608. doi: 10.1186/s12951-024-02875-w.
8
Mitophagy and cGAS-STING crosstalk in neuroinflammation.神经炎症中的线粒体自噬与cGAS-STING相互作用
Acta Pharm Sin B. 2024 Aug;14(8):3327-3361. doi: 10.1016/j.apsb.2024.05.012. Epub 2024 May 13.
9
Nanomedicines for Dry Eye Syndrome: Targeting Oxidative Stress with Modern Nanomaterial Strategies.纳米药物治疗干眼综合征：用现代纳米材料策略靶向氧化应激。
Molecules. 2024 Aug 7;29(16):3732. doi: 10.3390/molecules29163732.
10
Application of Silicone in Ophthalmology: A Review.硅酮在眼科中的应用：综述
Materials (Basel). 2024 Jul 12;17(14):3454. doi: 10.3390/ma17143454.
含马来酸噻吗洛尔的聚己内酯基电纺纳米纤维作为青光眼治疗缓释装置的研制与评价：在马眼中的评价
Res Pharm Sci. 2022 Sep 8;17(5):468-481. doi: 10.4103/1735-5362.355196. eCollection 2022 Oct.
4
Recent advancements in polymeric nanofibers for ophthalmic drug delivery and ophthalmic tissue engineering.用于眼科药物递送和眼科组织工程的聚合物纳米纤维的最新进展。
Biomater Adv. 2022 Oct;141:213124. doi: 10.1016/j.bioadv.2022.213124. Epub 2022 Sep 17.
5
Plant polysaccharides as novel biomaterials for microcapsule construction and therapeutics delivery.植物多糖作为新型生物材料用于微胶囊构建和治疗药物递送。
Int J Pharm. 2022 Sep 25;625:122137. doi: 10.1016/j.ijpharm.2022.122137. Epub 2022 Aug 24.
6
Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.基于纳米技术的眼部疾病诊断和治疗的最新进展，综述与更新。
J Nanobiotechnology. 2022 Aug 2;20(1):361. doi: 10.1186/s12951-022-01567-7.
7
Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema.治疗糖尿病性黄斑水肿的当前和新型治疗方法。
Cells. 2022 Jun 17;11(12):1950. doi: 10.3390/cells11121950.
8
Glutathione-Sensitive Nanoglue Platform with Effective Nucleic Acids Gluing onto Liposomes for Photo-Gene Therapy.谷胱甘肽响应性纳米胶束平台，可将有效核酸黏附到脂质体上用于光基因治疗。
ACS Appl Mater Interfaces. 2022 Jun 8;14(22):25126-25134. doi: 10.1021/acsami.2c04022. Epub 2022 May 24.
9
Nanocarriers for ocular drug delivery: current status and translational opportunity.用于眼部药物递送的纳米载体：现状与转化机遇
RSC Adv. 2020 Jul 24;10(46):27835-27855. doi: 10.1039/d0ra04971a. eCollection 2020 Jul 21.
10
[Treatment of age-related macular degeneration: new insights and developments].[年龄相关性黄斑变性的治疗：新见解与进展]
Ned Tijdschr Geneeskd. 2022 Mar 10;166:D6416.